Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications

NCT02949011 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT02949011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02949011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
January 11, 2017
Completion date
April 20, 2018
Enrollment
2,184 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

influenza